The DOI matches its Crossref record.
Antagonism of metabotropic glutamate receptor type 5 attenuates l‐DOPA‐induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson’s disease
Abstract
Metabotropic glutamate receptor type 5 (mGluR5) modulates dopamine and glutamate neurotransmission at central synapses. In this study, we addressed the role of mGluR5 in l‐DOPA‐induced dyskinesia, a movement disorder that is due to abnormal activation of both dopamine and glutamate receptors in the basal ganglia. A selective and potent mGluR5 antagonist, 3‐[(2‐methyl‐1,3‐thiazol‐4‐yl)ethynyl] pyridine, was tested for its ability to modulate molecular, behavioural and neurochemical correlates of dyskinesia in 6‐hydroxydopamine‐lesioned rats treated with l‐DOPA. The compound significantly attenuated the induction of abnormal involuntary movements (AIMs) by chronic l‐DOPA treatment at doses that did not interfere with the rat physiological motor activities. These effects were paralleled by an attenuation of molecular changes that are strongly associated with the dyskinesiogenic action of l‐DOPA (i.e. up‐regulation of prodynorphin mRNA in striatal neurons). Using in vivo microdialysis, we found a temporal correlation between the expression of l‐DOPA‐induced AIMs and an increased GABA outflow within the substantia nigra pars reticulata. When co‐administered with l‐DOPA, 3‐[(2‐methyl‐1,3‐thiazol‐4‐yl)ethynyl] pyridine greatly attenuated both the increase in nigral GABA levels and the expression of AIMs. These data demonstrate that mGluR5 antagonism produces strong anti‐dyskinetic effects in an animal model of Parkinson’s disease through central inhibition of the molecular and neurochemical underpinnings of l‐DOPA‐induced dyskinesia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Duty, S., & Jenner, P. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01426.x · Cited by 753
Metabotropic glutamate receptors: From the workbench to the bedside
Nicoletti, F., Bockaert, J., Collingridge, G. L., Conn, P. J., Ferraguti, F., Schoepp, D. D., Wroblewski, J. T., & Pin, J. P. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.10.022 · Cited by 653
Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap
Calabresi, P., Filippo, M. D., Ghiglieri, V., Tambasco, N., & Picconi, B. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70218-0 · Cited by 388
The Pharmacology of l-DOPA-Induced Dyskinesia in Parkinson’s Disease
Huot, P., Johnston, T. H., Koprich, J. B., Fox, S. H., & Brotchie, J. M. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005678 · Cited by 324
The serotonergic system in Parkinson's disease
Huot, P., Fox, S. H., & Brotchie, J. M. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.08.004 · Cited by 195
Metadata
- Authors
- Mela, F., Marti, M., Dekundy, A., Danysz, W., Morari, M., & Cenci, M. A.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2007-01-22
- Volume
- 101
- Issue
- 2
- Pages
- 483-497
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W1971698832
- Cited by
- 205
- References
- 0
- FWCI
- 11.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antagonism of metabotropic glutamate receptor type 5 attenuates l‐DOPA‐induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson’s disease. https://app.cochat.ai/papers/10.1111/j.1471-4159.2007.04456.x
- The paper
- Mela, F., Marti, M., Dekundy, A., Danysz, W., Morari, M., & Cenci, M. A. (2007). Antagonism of metabotropic glutamate receptor type 5 attenuates l‐DOPA‐induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson’s disease. Journal of Neurochemistry. https://doi.org/10.1111/j.1471-4159.2007.04456.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.